---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-037113"
form_type: "8-K"
ticker: "STXS"
cik: "0001289340"
company_name: "Stereotaxis, Inc."
filed_at: "2026-08-11T20:05:17+00:00"
generated_at: "2026-08-11T20:06:18.510110+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Stereotaxis Q2 2026 revenue $7.7M; robotic catheter revenue tops $1M, up 270% sequentially

## Summary
- Q2 2026 revenue $7.7M; system revenue $1.5M (vs $3.0M year-ago), recurring revenue $6.2M (vs $5.8M year-ago).
- Net loss widened to $4.5M from $3.8M year-ago; adjusted net loss $2.0M vs $1.3M; operating loss $4.6M.
- Robotic catheter revenue surpassed $1M in the quarter, growing 270% sequentially; first US GenesisX purchase announced.
- Cash $10.5M with no debt at June 30, 2026; expects recurring revenue ~$7M in Q3 and ~$8M in Q4 2026.
- Completed Robocath acquisition; multiple Synchrony OR systems sold after April FDA clearance; cash flow profitability targeted 1H 2027.

## SEC filing metadata
- accession: 0001493152-26-037113
- form_type: 8-K
- ticker: STXS
- cik: 0001289340
- company_name: Stereotaxis, Inc.
- filed_at: 2026-08-11T20:05:17+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1289340/000149315226037113/0001493152-26-037113-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1289340/000149315226037113/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-037113
- JSON: https://secwatch.observer/filing/0001493152-26-037113.json
- Plain text: https://secwatch.observer/filing/0001493152-26-037113.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.